表现为磨玻璃影的肺腺癌EGFR突变状态预测:radiomics模型在临床转化中的应用
本研究基于636例磨玻璃影(GGO)特征肺腺癌患者的术前CT建立radiomics模型,从1476个特征中筛选102个特征预测EGFR突变状态,训练集、内部验证集和外部验证集AUC分别为0.838、0.822和0.803,均优于临床模型;联合模型未显示额外获益。在辅助EGFR-TKI治疗且携带未切除GGO的患者队列中应用该模型后,EGFR-TKI疗效显著提高(缓解率25.9% vs 53.8%,p=0.006)。
要点
- 基于CT的radiomics模型(含102个特征)可无创预测GGO肺腺癌EGFR突变状态。
- 模型在内部和外部验证集AUC分别为0.822和0.803,优于临床模型。
- 在辅助EGFR-TKI治疗队列中应用模型后,缓解率从25.9%提升至53.8%(p=0.006)。
核心结论
- 该radiomics模型可作为无创、省时的方法预测表现为GGO的肺腺癌EGFR突变状态,并在辅助EGFR-TKI治疗队列中显著提高EGFR-TKI疗效(缓解率25.9% vs 53.8%,p=0.006)。
研究设计与样本
- 研究纳入636例接受GGO病灶切除的肺腺癌患者(训练集464例、内部验证集100例、外部验证集72例),收集临床病理信息和术前CT图像,采用梯度提升决策树(GBDT)提取1476个radiomics特征。
诊断标准与关键数值
- radiomics模型包含102个筛选特征,预测EGFR突变状态(突变型或野生型)的AUC在训练集、内部验证集和外部验证集分别为0.838、0.822和0.803;临床模型对应AUC分别为0.674、0.730和0.746;联合radiomics与临床模型AUC分别为0.846、0.816和0.811。
临床应用与阅片要点
- 原文结论认为该radiomics模型可作为无创、省时的方法预测表现为GGO的肺腺癌EGFR突变状态;在辅助EGFR-TKI治疗且携带未切除GGO的患者队列中,应用模型后EGFR-TKI缓解率显著提高(25.9% vs 53.8%,p=0.006)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: This study aimed to establish a non-invasive radiomics model based on computed tomography (CT), with favorable sensitivity and specificity to predict EGFR mutation status in GGO-featured lung adenocarcinoma subsequently guiding the administration of targeted therapy.
METHODS: Clinical-pathological information and preoperative CT images of 636 lung adenocarcinoma patients (464, 100, and 72 in the training, internal, and external validation sets, respectively) that underwent GGO lesions resection were included. A total of 1476 radiomics features were extracted with gradient boosting decision tree (GBDT).
RESULTS: The established radiomics model containing 102 selected features showed an encouraging discrimination performance of EGFR mutation status (mutant or wild type), and the predictive ability was superior to that of the clinical model (AUC: 0.838 vs. 0.674, 0.822 vs. 0.730, and 0.803 vs. 0.746 for the training, internal validation, and external validation sets, respectively). The combined radiomics plus clinical model showed no additional benefit over the radiomics model in predicting EGFR status (AUC: 0.846 vs. 0.838, 0.816 vs. 0.822, and 0.811 vs. 0.803, respectively, in three cohorts). Uniquely, this model was validated in a cohort of lung adenocarcinoma patients who have undertaken adjuvant EGFR-TKI treatment and harbored unresected GGOs during the medication, leading to a significantly improved potency of EGFR-TKIs (response rate: 25.9% vs. 53.8%, p = 0.006; before and after prediction, respectively).
CONCLUSION: This presented radiomics model can be served as a non-invasive and time-saving approach for predicting the EGFR mutation status in lung adenocarcinoma presenting as GGO.
KEY POINTS: • We developed a GGO-specific radiomics model containing 102 radiomics features for EGFR mutation status differentiation. • An AUC of 0.822 and 0.803 in the internal and external validation cohorts, respectively, were achieved. • The radiomics model was utilized in clinical translation in an adjuvant EGFR-TKI treatment cohort with unresected GGOs. A significant improvement in the potency of EGFR-TKIs was achieved (response rate: 25.9% vs. 53.8%, p = 0.006; before and after prediction).
引用
- Cheng B, Deng H, Zhao Y, et al. Predicting EGFR mutation status in lung adenocarcinoma presenting as ground-glass opacity: utilizing radiomics model in clinical translation. Eur Radiol. 2022. PMID: 35348863. doi:10.1007/s00330-022-08673-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。